ClinicalTrials.Veeva

Menu
B

Bioclinical Research Alliance | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Sugar
Metformin
JNJ-77242113
ABP-671
Tirzepatide
EDP-235
Obeldesivir
Cagrilintide
BI 685509
S-217622

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 14 total trials

A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (REIMAGINE 5)

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Enrolling
Diabetes Mellitus, Type 2
Drug: Cagrilintide
Drug: Semaglutide

This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Placebo
Drug: Semaglutide

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Semaglutide

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare th...

Active, not recruiting
Gout
Other: Placebo
Drug: Allopurinol

Trial sponsors

Novo Nordisk logo
A
Janssen (J&J Innovative Medicine) logo
Boehringer Ingelheim logo
Enanta Pharmaceuticals logo
Gilead Sciences logo
M
Pfizer logo
Shionogi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems